Background Patients who have had inadequate response to tumour necrosis factor inhibitors
have fewer treatment options and are generally more treatment refractory to subsequent …

Objective To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2)
inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). Methods In this double-…

Objectives The Assessment of SpondyloArthritis international Society (ASAS) MRI working
group (WG) was convened to generate a consensus update on standardised definitions for …

Objectives Here, we present the reported incidence rates of inflammatory bowel disease (IBD)
in patients receiving treatment with secukinumab for psoriasis (PsO), psoriatic arthritis (…

Objective: To describe the epidemiology and clinical spectrum of reactive arthritis (ReA)
following culture-confirmed infection with bacterial enteric pathogens in a population-based …

Objective Secukinumab, a fully human anti-IL-17A monoclonal antibody, provided rapid and
sustained improvements in signs and symptoms of ankylosing spondylitis (AS) over 2 years …

OBJECTIVE: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain,
fatigue, disrupted sleep, depression, and physical deconditioning. In this article, we review the …

Objective To evaluate golimumab's effect on MRI-detected spinal inflammation in ankylosing
spondylitis (AS). Methods Patients were randomly assigned to subcutaneous injections of …

… Address correspondence to Atul A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases
(OP09)… Deodhar had full access to all of the data in the study and takes responsibility for the …

REPORT of AS requires the presence of 1 or more clinical criteria: These include low back
pain and stiffness, lasting longer than 3 months, that improve with exercise but do not improve …